Gilead Sciences, Inc. (NASDAQ:GILD) rose 0.18% to $39.61 after the company last
week, reported that its third-quarter net income climbed 5 percent,topping
topping analysts’ expectations.
Gilead
Sciences, Inc. is a biopharmaceutical company that discovers, develops and
commercializes therapeutics. The Company has operations in North America,
Europe and Australia.
SuperGen, Inc. (NASDAQ:SUPG) soared
21.03% to $2.82. SuperGen's net income for the quarter surged to $3.89 million
from $0.83 million last year. On a per-share basis, earnings rose to $0.06 from
$0.01 last year.
SuperGen's
total quarterly revenues grew to $13.38 million from $10.36 million in the
comparable quarter a year ago.
Over
the past 52-week, the stock traded within the range of $1.71-$3.80.
Bristol
Myers Squibb Co. (NYSE:BMY) dropped 1.10% to $26.86. The
company earned $949 million in the third quarter, off from $966 million in the
same period a year ago, financial results showed. Sales edged up to $4.8
billion from $4.79 billion.
The
stock opened at $27.01 and was trading within the range of $26.69-$27.08.
Alkermes, Inc. (NASDAQ:ALKS) advanced
0.65% to $10.88. Last week, UBS downgraded Alkermes from Buy to Neutral. The
price target was lowered from $18 to $11.
This
week, the company announced positive topline results from a phase 1 clinical
study of an investigational combination of ALKS 33, one of Alkermes’
candidates, and buprenorphine, an existing medication for the treatment of
opioid addiction, for the treatment of cocaine addiction.
Over
the past 52-week, the stock traded within the range of $7.54-$16.10.
Article published by Wall Street Grand. Visit the Wall Street Grand Club today. For our full disclosure please visit - http://www.wallstreetgrand.com/disclosure.html
